PRINCETON, N.J., SHANGHAI and SUZHOU, China, Dec. 2, 2024 /PRNewswire/ -- Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics, today announced that it has entered into an exclusive option agreement with GSK for a potentially best-in-class ADC candidate, DB-1324. Under the agreement, DualityBio will grant GSK an exclusive option to obtain a license to develop and commercialize DB-1324 worldwide (excluding mainland China, Hong Kong, and Macau) (the "Option").